

publishes abstracts of information collection requests under review by the Office of Management and Budget (OMB), in compliance with the Paperwork Reduction Act of 1995 (44 U.S.C. Chapter 35). To request a copy of the clearance requests submitted to OMB for review, e-mail paperwork@hrsa.gov or call the HRSA Reports Clearance Office on (301) 443-1129.

The following request has been submitted to the Office of Management and Budget for review under the Paperwork Reduction Act of 1995:

Proposed Project: The National Health Service Corps (NHSC) Scholarship Program Application (OMB No. 0915-0146)—[Revision]

The National Health Service Corps (NHSC) Scholarship Program provides the NHSC with the health professionals

it requires to carry out its mission of providing primary health care to populations residing in areas of greatest need. Under this program, health professions students are awarded scholarships in return for service in a federally designated Health Professional Shortage Area (HPSA). Students are supported who are well qualified to participate in the NHSC Scholarship Program and who want to assist the NHSC in its mission, both during and after their period of obligated service. The NHSC Scholarship Program forms are used to collect relevant information necessary to make award determinations. Scholars are selected for these competitive awards based on the information provided in the application, forms, and supporting documentation. Awards are made to applicants who demonstrate a high potential for providing quality primary health care

services in HPSAs. The program forms include the following: The NHSC Scholarship Program Application, Academic and Non-Academic Evaluation Letters (formerly Letters of Recommendation), the Authorization to Release Information, the Verification of Acceptance/Good Standing Report, the Receipt of Exceptional Financial Need Scholarship, the Verification Regarding Disadvantaged Background and the Acceptance/Declination Form. Also included are the Data Collection Worksheet, which is completed by the schools of program participants, the Deferment Request Form, which is completed by program participants and the Six-Month Service Obligation Verification Form, which is completed by program participants and their sites.

The annual estimate of burden for applicants is as follows:

Instrument	Number of respondents	Responses/ respondent	Total responses	Hours per response	Total burden hours
NHSC Scholarship Program Application	1,800	1	1,800	2.0	3,600
Evaluation Letters	1,800	2	3,600	.50	1,800
Authorization to Release Information	1,800	1	1,800	.10	180
Verification of Acceptance/Good Standing Report	1,800	1	1,800	.25	450
Receipt of Exceptional Financial Need Scholarship	100	1	100	.25	25
Verification Regarding Disadvantaged Background	300	1	300	.25	75
Acceptance/Declination Form	250	1	250	.10	25
Total			9,400		6,155

The annual estimate of burden for participants/schools/sites is as follows:

Instrument	Number of respondents	Responses/ respondent	Total responses	Hours per response	Total burden hours
Data Collection Worksheet	400	1	400	1.0	400
Deferment Request Form	60	1	60	.25	15
Six-Month Service Obligation Verification Form	700	2	1,400	.50	700
Total			1,860		1,115

Written comments and recommendations concerning the proposed information collection should be sent within 30 days of this notice to the OMB desk officer for HRSA, either by e-mail to OIRA_submission@omb.eop.gov or by fax to 202-395-6974. Please direct all correspondence to the "attention of the OMB desk officer for HRSA."

Dated: December 21, 2010.

Robert Hendricks,

Director, Division of Policy and Information Coordination.

[FR Doc. 2010-32562 Filed 12-27-10; 8:45 am]

BILLING CODE 4165-15-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Service Administration

Advisory Committee on Interdisciplinary, Community-Based Linkages; Notice of Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), notice is hereby given of the following meeting:

Name: Advisory Committee on Interdisciplinary, Community-Based Linkages (ACICBL).

Dates and Times: January 27, 2011, 8:30 a.m. to 5 p.m., EST. January 28, 2011, 8:30 a.m. to 4 p.m., EST.

Place: Hilton Washington DC/ Rockville Executive Meeting Center, 1750 Rockville Pike, Rockville, MD 20852. Telephone: 301-468-1100.

Status: The meeting will be open to the public.

Purpose: The members of the ACICBL will advance the planning required to develop their 11th Annual Report for the Secretary of the Department of Health and Human Services (the Secretary) and Congress, using the working topic, Continuing Education, Professional Development and Lifelong Learning for the 21st Century Health Care Workforce. The meeting will provide the planning and writing sub-committees with the opportunity to review the urgent issues related to the

training programs, identify resources that will address the gaps and further strengthen the outcomes from these efforts, examine testimony from the experts in the field, and offer recommendations for improvement of these training programs to the Secretary and the Congress.

Agenda: The ACICBL agenda includes an overview of the Committee's general business activities, an orientation for the eight newly appointed members, presentations by and dialogue with experts, and discussion sessions specific to the development of recommendations to be addressed in the 11th Annual ACICBL Report. Agenda items are subject to change as dictated by the priorities of the Committee.

SUPPLEMENTARY INFORMATION: Requests to make oral comments or to provide written comments to the ACICBL should be sent to Dr. Joan Weiss, Designated Federal Official at the contact information below. Individuals who plan to attend the meeting and need special assistance should notify Dr. Weiss at least 10 days prior to the meeting, using the address and phone number below. Members of the public will have the opportunity to provide comments at the meeting.

FOR FURTHER INFORMATION CONTACT: Anyone requesting additional details should contact Dr. Joan Weiss, Designated Federal Official within the Bureau of Health Professions, Health Resources and Services Administration. Dr. Weiss may be reached by one of the three following methods: (1) Via written request to: Dr. Joan Weiss, Designated Federal Official, Bureau of Health Professions, Health Resources and Services Administration, Parklawn Building, Room 9-36, 5600 Fishers Lane, Rockville, Maryland 20857; (2) via telephone at (301) 443-6950; or (3) via e-mail at jweiss@hrsa.gov. In the absence of Dr. Weiss, CAPT Norma J. Hatot, Senior Nurse Consultant, may be contacted via telephone at (301) 443-2681 or by e-mail at nhatot@hrsa.gov.

Dated: December 21, 2010.

Robert Hendricks,

Director, Division of Policy and Information Coordination.

[FR Doc. 2010-32560 Filed 12-27-10; 8:45 am]

BILLING CODE 4165-15-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of Federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

Hesperetin Therapy for Metabolic Syndrome and Insulin Resistance

Description of Technology: Hesperidin is a flavonoid compound found in citrus fruits. Large epidemiological studies have linked increased consumption of flavonoid-rich foods, such as citrus, with reduced cardiovascular morbidity and mortality. Investigators from the National Center for Complementary and Alternative Medicine have demonstrated that administration of oral hesperidin to patients with metabolic syndrome attenuates biomarkers of inflammation and improves blood vessel relaxation, lipid cholesterol profiles, and insulin sensitivity when compared to controls. Thus, hesperidin and its active aglycone form, hesperetin, may be effective agents for the treatment of diabetes, obesity, metabolic syndrome, dyslipidemias, and their cardiovascular complications including hypertension, atherosclerosis, coronary heart disease, and stroke. This technology discloses methods for using a hesperetin composition to treat metabolic syndrome and insulin resistance.

Applications: Therapeutics for metabolic syndrome and insulin resistance.

Development Status: Clinical trial data available.

Inventors: Michael J. Quon and Ranganath Muniyappa (NCCAM).

Publications: Manuscript in preparation.

Patent Status: U.S. Provisional Application No. 61/369,229 filed 30 July 2010 (HHS Reference No. E-148-2010/0-US-01).

Licensing Status: Available for licensing.

Licensing Contact: Tara L. Kirby, Ph.D.; 301-435-4426; kirbyt@mail.nih.gov.

Substituted Triazine and Purine Compounds for the Treatment of Chagas Disease and African Trypanosomiasis

Description of Technology: Parasitic protozoa are responsible for a wide variety of infections in both humans and animals. Trypanosomiasis poses health risks to millions of people across multiple countries in Africa and North and South America. Visitors to these regions, such as business travelers and tourists, are also at risk for contracting parasitic diseases. There are two types of African trypanosomiasis, also known as sleeping sickness. One type is caused by the parasite *Trypanosoma brucei gambiense*, and the other is caused by the parasite *Trypanosoma brucei rhodesiensi*. If left untreated, African sleeping sickness results in death. Chagas disease, caused by *Trypanosoma cruzi* (*T. cruzi*), affects millions of people in Mexico and South and Central America. Untreated, Chagas disease causes decreased life expectancy and can also result in death.

The subject invention covers novel triazine and purine compounds that are inhibitors of key proteases (cruzain and Rhodesian) of the parasites *Trypanosoma brucei rhodesiensi* and *Trypanosoma cruzi*, respectively.

Applications: Prophylactic and therapeutic treatment of African trypanosomiasis and Chagas disease.

Advantages

- Novel compounds against the cysteine proteases, cruzain and rhodesain.
- Compounds possess low nanomolar inhibitory potential against cruzain and rhodesain.

Development Status: *In vitro* and *in vivo* data are available upon request and upon execution of an appropriate confidentiality agreement.

Inventors: Craig J. Thomas *et al.* (NHGRI).

Related Publication: BT Mott *et al.* Identification and optimization of inhibitors of Trypanosomal cysteine